Januvia Tablets (Sitagliptin Phosphate Monohydrate Tablets)

Januvia Tablets (Sitagliptin Phosphate Monohydrate Tablets) Januvia Tablets (Sitagliptin Phosphate Monohydrate Tablets) are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as monotherapy when metformin is considered inappropriate due to intolerance; or in combination with other anti-hyperglycaemic agents, including Controllinginsulin. high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Sitagliptin is a diabetes drug that works by increasing levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes.

Chemical Structure

Uses of Januvia Tablets

Januvia (Sitagliptin Phosphate Monohydrate Tablets) is used alone or together with other medicines (eg, Insulin, Glimepiride, Metformin, or Pioglitazone) and with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. Sitagliptin helps to control blood sugar levels by increasing substances in the body that make the pancreas release more insulin. It also signals the liver to stop producing sugar (glucose) when there is too much sugar in the blood. This medicine does not help patients who have insulin-dependent or type 1 diabetes. Januvia Tablets have not been studied in patients with a history of pancreatitis.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue Januvia (Sitagliptin Phosphate Monohydrate Tablets). Heart failure: Heart failure has been observed with two other members of the DPP -4 inhibitor class. Consider risks and benefits of Januvia in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Assessment of renal function is recommended prior to initiating Januvia and periodically thereafter.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required . Hypersensitivity Reactions: There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with Januvia such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Promptly stop Januvia, assess for other potential causes, institute appropriate monitoring and treatment.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Warnings

Severe and Disabling Arthralgia: Has been rep orted in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate. Bullous Pemphigoid: There have been postmarketing reports requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue Januvia. Januvia has no or negligible influence on the ability to drive and use machines. However, when driving or using machines, it should be taken into account that dizziness and somnolence have been reported. In addition, patients should be alerted to the risk of hypoglycaemia when Januvia is used in combination with a sulphonylurea or with insulin.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Januvia Tablets Side Effects

Side effects reported in 5% or more of patients treated with Sitagliptin Phosphate Monohydrate (Januvia tablets) and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache. In the add -on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with Januvia compared to placebo.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Overdose

In the event of an overdose with Sitagliptin Phosphate Monohydrate (Januvia tablets), contact the Poison Control Center. In the event of an overdose, it is reasonable to employ supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as dictated by the patient's clinical status. Sitagliptin is modestly dialyzable. In clinical studies , approximately 13.5% of the dose was removed over a 3- to 4-hour hemodialysis session. Prolonged hemodialysis may be considered if clinically appropriate. It is no t known if sitagliptin is dialyzable by peritoneal dialysis. URL: https://www.clearskypharmacy.biz/januvia-tablets.html

Januvia Tablets During Pregnancy

Sitagliptin Phosphate Monohydrate (Januvia tablets) has been classified by the US FDA as Pregnancy Category B. Reproduction studies have been performed in rats and rabbits. Doses of Sitagliptin Phosphate Monohydrate (Januvia tablets) up to 125 mg/kg (approximately 12 times the human exposure at the maximum recommended human dose) did not impair fertility or harm the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

URL: https://www.clearskypharmacy.biz/januvia-tablets.html